Method: The level of plasma sLOX-1 was determined in 93 Japanese patients with biopsy-proven NAFLD. We evaluated relationships of plasma sLOX-1 to physical and clinical laboratory data, and liver histological evaluations, such as NAFLD activity sore (NAS) (steatosis, inflammation, and ballooning), and fibrosis. The diagnosis www.selleckchem.com/products/Everolimus(RAD001).html of NASH was based on Matteoni’s classification. Results: Seventeen patients were his-tologically classified into NASH (53 had stage 0-2 fibrosis and 17 had stage 3-4), and 23 patients were classified into NAFL. There were not any statistical differences in sLOX-1 levels between the two groups. The

plasma level of sLOX-1 was positively correlated with hyaluronic acid (r=0.248, p=0.021), typeIV collagen 7s (r=0.255, p=0.014), and histological fibro-sis stage (r=0.225, p=0.03), but not with NAS. The area under the receiver operating characteristic curve for sLOX-1 in separating patients with (stage 3-4) and without severe fibrosis (stage 0-2) was 0.625 with an optimal cutoff point of 140ng/l. The prevalence of patients with sLOX-1 more than 140ng/l see more were significantly higher in those with severe fibrosis

(82.4%) than those without severe fibrosis (47.4%, p=0.003). In multiple regressions, the association between higher sLOX-1 (>140ng/l) and NASH severe fibrosis persisted after adjusting for age, gender, body mass index, and insulin resistance. Conclusion: Circulating plasma sLOX-1 level was an independent factor

for predicting severe fibrosis in NAFLD patients. The association of sLOX-1 and severe fibrosis suggests a possible link between atherosclerosis and hepatic fibrosis in NAFLD. LOX-1 may be a novel, exciting target for drug therapies in NAFLD patients. Atorvastatin Disclosures: Kohichiroh Yasui – Grant/Research Support: AstraZeneca K.K., CHUGAI Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., FUJIFILM Medical Co., Ltd., Merck Serono, MSD K.K., Otsuka Pharmaceutical Co., Ltd. Yoshito Itoh – Grant/Research Support: MSD KK, Bristol-Meyers Squibb, Dain-ippon Sumitomo Pharm. Co., Ltd., Otsuka Pharmaceutical Co., Chugai Pharm Co., Ltd, Mitsubish iTanabe Pharm. Co.,Ltd., Daiichi Sankyo Pharm. Co.,Ltd., Takeda Pharm. Co.,Ltd., AstraZeneca K.K.:, Eisai Co.,Pharm.Ltd, FUJIFILM Medical Co.,Ltd. The following people have nothing to disclose: Hiroshi Ishiba, Yoshio Sumida, Saiyu Tanaka, Kazuyuki Kanemasa, Yuya Seko, Akira Okajima, Tasuku Hara, Hiroyoshi Taketani, Kanji Yamaguchi, Michihisa Moriguchi, Hironori Mitsuyoshi, Masahito Minami Background & Aims: Nonalcoholic steatohepatitis (NASH), the potentially progressive form of nonalcoholic fatty liver disease (NAFLD) can lead to fibrosis and cirrhosis. Current treatment is limited to weight loss, exercise and the control of metabolic risk factors. More effective pharmacotherapies are necessary.